Name of opportunity: 👀
Alcon
One to keep an eye on: 👁️
Analysts have noted that Alcon is well-positioned to grow and make money, as the company is a spinoff from Novartis five years ago. It has been noted that spinoffs from large companies can grow fast and provide a great deal of value for investors, as they are smaller and more efficient and agile than the parent company, but take over some of the parent company’s operations. Alcon’s Q1 results look encouraging for shareholders.
How hot is this investment opportunity? 🔥🔥🔥
The company released its first quarter sales in May, with sales of $2.4 billion, up 5% from the first quarter of 2023. Net sales were US$2,444, higher than last year’s Q1 figure of US$2,333. If this growth continues, this would be great news for investors. The stock’s value is up 15.94% in the last 6 months, although it has dipped slightly in the last week.
Alcon also gives dividends to investors, paying out US$132 this May. The next dividend payment will be next year, at a dividend of CHF 0.24 per share - the company is Swiss.
The company has predicted that the market for eye surgery and contact lenses will continue to grow as populations get older around the world. The company estimates the global market is currently worth US$34bn.
Approved by doctors :⚕️
Fund manager Alistair Wittet has observed that Alcon has a very loyal customer base, with doctors consistently opting to provide Alcon products to their patients and use the company’s equipment. Alcon AG reports its activities into two segments: Surgical and Vision Care. The company works in over 50 countries and has patients in more than 140 countries. As well as surgical equipment for vision correction and the treatment of cataracts, Alcon produces contact lenses, dry eye treatments and glaucoma prescription medications.
Which neme?: 🔍
Search directly for Alcon
Download Nemo to take a look at Alcon stock
